Aliases & Classifications for Hypoxia

MalaCards integrated aliases for Hypoxia:

Name: Hypoxia 54 73

External Ids:

UMLS 73 C0242184

Summaries for Hypoxia

Novus Biologicals : 56 Hypoxia is a pathological condition in which the body as a whole (generalized hypoxia) or region of the body (tissue hypoxia) is deprived of adequate oxygen supply. Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease. Hypoxia inducible factor-1 (HIF-1) is a transcription factor that regulates adaptive responses to a lack of oxygen in mammalian cells. HIF-1 consists of two proteins, HIF-1 alpha and HIF-1 beta. HIF-1 alpha accumulates under hypoxic conditions whereas HIF-1 beta is constitutively expressed. HIF-1 alpha is an important mediator of the hypoxic response of tumor cells and controls the up-regulation of a number of factors important for solid tumor expansion including the angiogenic factor VEGF.

MalaCards based summary : Hypoxia is related to acute mountain sickness and polycythemia, and has symptoms including anoxemia, apnea and cachexia. An important gene associated with Hypoxia is KMT2A (Lysine Methyltransferase 2A
Our studies demonstrate that HOTAIR expression is upregulated under hypoxia in colon cancer and several other types of cancer cells. 
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Pathways in cancer. The drugs Zinc and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include endothelial, lung and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

NINDS : 54 Cerebral hypoxia refers to a condition in which there is a decrease of oxygen supply to the brain even though there is adequate blood flow. Drowning, strangling, choking, suffocation, cardiac arrest, head trauma, carbon monoxide poisoning, and complications of general anesthesia can create conditions that can lead to cerebral hypoxia. Symptoms of mild cerebral hypoxia include inattentiveness, poor judgment, memory loss, and a decrease in motor coordination. Brain cells are extremely sensitive to oxygen deprivation and can begin to die within five minutes after oxygen supply has been cut off. When hypoxia lasts for longer periods of time, it can cause coma, seizures, and even brain death.  In brain death, there is no measurable activity in the brain, although cardiovascular function is preserved. Life support is required for respiration.

Related Diseases for Hypoxia

Diseases related to Hypoxia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 555)
# Related Disease Score Top Affiliating Genes
1 acute mountain sickness 31.1 EGLN1 HIF1A HIF1AN VHL
2 polycythemia 30.6 EGLN1 EPAS1 HIF1A VHL
3 renal cell carcinoma, nonpapillary 30.5 EPAS1 HIF1A HIF1AN MTOR VHL
4 fumarate hydratase deficiency 30.3 HIF1A VHL
5 erythrocytosis, familial, 2 30.1 EGLN1 EPAS1 HIF1A VHL
6 primary polycythemia 30.0 EGLN1 EPAS1 VHL
7 retinal hemangioblastoma 29.8 EPAS1 HIF1A VHL
8 clear cell renal cell carcinoma 29.8 HIF1A MTOR VHL
9 cerebral hypoxia 12.4
10 respiratory underresponsiveness to hypoxia and hypercapnia 11.9
11 polycythemia due to hypoxia 11.9
12 anoxia 11.5
13 exudative vitreoretinopathy 1 11.2
14 pulmonary edema 11.1
15 brain ischemia 11.1
16 apnea of prematurity 11.1
17 methemoglobinemia 11.1
18 tempi syndrome 11.1
19 asphyxia neonatorum 11.1
20 neonatal hypoxic and ischemic brain injury 11.1
21 methemoglobinemia due to deficiency of methemoglobin reductase 10.9
22 autosomal dominant secondary polycythemia 10.8 EGLN1 EPAS1
23 hantavirus pulmonary syndrome 10.8
24 telangiectasia, hereditary hemorrhagic, type 4 10.8
25 exudative vitreoretinopathy 7 10.8
26 leukostasis 10.8
27 pneumothorax, primary spontaneous 10.8
28 exudative vitreoretinopathy 4 10.8
29 methemoglobinemia and ambiguous genitalia 10.8
30 typical congenital nemaline myopathy 10.8
31 exudative vitreoretinopathy 2, x-linked 10.8
32 congenital laryngeal palsy 10.8
33 chronic mountain sickness 10.8
34 exudative vitreoretinopathy 6 10.8
35 exudative vitreoretinopathy 5 10.8
36 severe acute respiratory syndrome 10.8
37 endotheliitis 10.7
38 cerebritis 10.6
39 lung cancer susceptibility 3 10.6
40 ischemia 10.6
41 polycystic kidney disease 10.4
42 breast cancer 10.4
43 prostatitis 10.4
44 neuronitis 10.4
45 pancreatitis 10.4
46 lung cancer 10.4
47 prostate cancer 10.3
48 hepatocellular carcinoma 10.3
49 pulmonary hypertension 10.3
50 squamous cell carcinoma 10.3

Graphical network of the top 20 diseases related to Hypoxia:



Diseases related to Hypoxia

Symptoms & Phenotypes for Hypoxia

UMLS symptoms related to Hypoxia:


anoxemia, apnea, cachexia, cheyne-stokes respiration, coughing, cyanosis, dyspnea, edema, fever, headache, hemoptysis, hoarseness, icterus, seizures, signs and symptoms, signs and symptoms, digestive, signs and symptoms, respiratory, sneezing, syncope, vertigo, chills, hyperoxia, motor symptom, skin symptoms, hot flushes, physical symptom, increased sweating, physical appearance, body

MGI Mouse Phenotypes related to Hypoxia:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.45 EGLN2 EGLN3 EP300 EPAS1 HIF1A HIF1AN
2 homeostasis/metabolism MP:0005376 10.41 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3 cellular MP:0005384 10.38 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
4 growth/size/body region MP:0005378 10.35 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
5 hematopoietic system MP:0005397 10.34 MTOR P4HTM RORA VHL ARNT CITED2
6 immune system MP:0005387 10.31 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
7 embryo MP:0005380 10.29 CITED2 EGLN1 EGLN2 EGLN3 EP300 EPAS1
8 mortality/aging MP:0010768 10.22 HIF1A HYOU1 KMT2A MTOR RORA TIGAR
9 craniofacial MP:0005382 10.21 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
10 muscle MP:0005369 10.18 EGLN1 EGLN2 EGLN3 EP300 EPAS1 HIF1A
11 liver/biliary system MP:0005370 10.09 EGLN2 EGLN3 EPAS1 HIF1A HIF1AN KMT2A
12 integument MP:0010771 10.08 ARNT EGLN1 EGLN2 EGLN3 HIF1A KMT2A
13 nervous system MP:0003631 10 EGLN3 EP300 EPAS1 HIF1A HYOU1 KMT2A
14 limbs/digits/tail MP:0005371 9.93 CITED2 EGLN2 EGLN3 HIF1A KMT2A VHL
15 normal MP:0002873 9.81 ARNT CITED2 EGLN3 EP300 HIF1A HIF1AN
16 neoplasm MP:0002006 9.8 HIF1A KMT2A TIGAR VHL ARNT EP300
17 renal/urinary system MP:0005367 9.61 ARNT CITED2 EGLN1 EP300 HIF1A KMT2A
18 respiratory system MP:0005388 9.28 RORA CITED2 EGLN1 EP300 EPAS1 HIF1A

Drugs & Therapeutics for Hypoxia

Drugs for Hypoxia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 672)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7440-66-6 23994
2
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
3
Metformin Approved Phase 4,Phase 2,Phase 1 657-24-9 14219 4091
4
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
5
Dopamine Approved Phase 4,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Budesonide Approved Phase 4,Phase 3,Phase 1 51333-22-3 63006 5281004
8
Succinylcholine Approved Phase 4 306-40-1 5314
9
Bosentan Approved, Investigational Phase 4,Phase 1 147536-97-8 104865
10
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
11
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 59467-70-8 4192
12
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068 160954
13
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
14
Ibuprofen Approved Phase 4,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
15
Sufentanil Approved, Investigational Phase 4,Not Applicable 56030-54-7 41693
16
Metoprolol Approved, Investigational Phase 4,Phase 2,Phase 3 37350-58-6, 51384-51-1 4171
17
Levodopa Approved Phase 4 59-92-7 6047
18
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
19
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
20
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
22
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 51-43-4 5816
23
Terbutaline Approved Phase 4 23031-25-6 5403
24
Adenosine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 58-61-7 60961
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 437-38-7 3345
26
Angiotensin II Approved, Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
27
Acetylcysteine Approved, Investigational Phase 4,Not Applicable,Early Phase 1 616-91-1 12035
28
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 7487-88-9 24083
29
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
30
Bromhexine Approved Phase 4 3572-43-8
31
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 329-65-7 838
32
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
33
Etomidate Approved Phase 4 33125-97-2 36339 667484
34
Benzydamine Approved Phase 4 100-46-9, 642-72-8 7504
35
Ranibizumab Approved Phase 4,Not Applicable 347396-82-1 459903
36
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable 2216-51-5 16666
37
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 59-66-5 1986
38
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
39
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
40
Captopril Approved Phase 4 62571-86-2 44093
41
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
42
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
43
Bupivacaine Approved, Investigational Phase 4,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
44
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
45
Methazolamide Approved Phase 4,Phase 1,Phase 2 554-57-4 4100
46
Nifedipine Approved Phase 4 21829-25-4 4485
47
Cetirizine Approved Phase 4 83881-51-0 2678
48
Ketorolac Approved Phase 4,Phase 1 74103-06-3, 66635-83-4 3826
49
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
50
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821

Interventional clinical trials:

(show top 50) (show all 1480)
# Name Status NCT ID Phase Drugs
1 Intermittent Hypoxia 2: Cardiovascular and Metabolism Unknown status NCT02058823 Phase 4 Placebo;Placebo;Valsartan;Amlodipine
2 Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia Unknown status NCT01449253 Phase 4 Sildenafil;Bosentan
3 Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery Unknown status NCT02133638 Phase 4 Sevoflurane;Propofol
4 Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children Unknown status NCT02205580 Phase 4 continuous intravenous sufentanil 0.02μg•kg-1•h-1 infusion;continuous intravenous sufentanil 0.03μg•kg-1•h-1 infusion;continuous intravenous sufentanil 0.04μg•kg-1•h-1 infusion
5 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
6 Postpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage Unknown status NCT01180192 Phase 4 oxygen
7 Home Oxygen Therapy in Bronchiolitis Unknown status NCT01216553 Phase 4
8 Effect of Acute Hyperglycemia on Renal Tissue Oxygenation Unknown status NCT02346149 Phase 4
9 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
10 CPAP in Liver Transplant Unknown status NCT00510770 Phase 4
11 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
12 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
13 Atropine Versus no Atropine for Neonatal Rapid Sequence Intubation Unknown status NCT01595399 Phase 4 atropine;Placebo
14 LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure Unknown status NCT00668408 Phase 4
15 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
16 Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers Completed NCT01873612 Phase 4
17 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females Completed NCT02356107 Phase 4 5-hydroxytryptophan and Creatine monohydrate
18 Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation Completed NCT01692821 Phase 4 100% oxygen breathing;15% oxygen in N2 breathing;12% oxygen in N2 breathing
19 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy Completed NCT02628106 Phase 4 Lipo-PGE1
20 Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects. Completed NCT00924833 Phase 4 placebo;Carvedilol;Nebivolol
21 Muscle Fatigue and Carbonic Anhydrase Inhibitors Completed NCT02758470 Phase 4 Acetazolamide;Methazolamide
22 CPAP in SAHS Patients With Hypertension Completed NCT02398032 Phase 4
23 Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure Completed NCT00517725 Phase 4 carvedilol;bisoprolol;Nebivolol
24 Single High Dose Vitamin C, E in Severe Birth Asphyxia Completed NCT01743742 Phase 4 Vitamin E, Vitamin C
25 Ambulatory Oxygen Effects on Muscles in COPD Completed NCT01722370 Phase 4 Oxygen;Medical air equivalent
26 Doxapram as an Additive to Propofol Sedation in Sedation for ERCP Completed NCT02171910 Phase 4 Doxapram;Placebo
27 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
28 The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy Completed NCT01725464 Phase 4
29 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
30 Safety Study of Analgesia After Craniotomy Surgery With End Tidal (ET) Carbon Dioxide (CO2) Monitoring Completed NCT01327677 Phase 4 Fentanyl;Fentanyl
31 Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Completed NCT01260662 Phase 4 Propofol;1:1 Propofol/Ketamine;4:1 Propofol/Ketamine
32 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
33 Propofol-Ketamine vs Remifentanyl-Ketamine for Sedation in Pediatric Patients Undergoing Colonoscopy Completed NCT02602743 Phase 4 Remifentanyl;Propofol;Ketamine
34 Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress Completed NCT01830335 Phase 4 Indomethacin;Placebo
35 The Use of Statins for Myocardial Death Prevention Completed NCT00772564 Phase 4 Atorvastatin
36 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP. Completed NCT00360659 Phase 4
37 Preventive Effect of the PRetreatment With Intravenous Nicorandil on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndEergoing Coronary Angiography (PRINCIPLE Study) Completed NCT01103336 Phase 4 pretreatment with intravenous nicorandil vs. placebo before coronary angiography
38 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Completed NCT02024386 Phase 4 Riociguat
39 Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition Completed NCT01545479 Phase 4 captopril 25mg
40 Ranibizumab in Patients With Branch Retinal Vein Occlusion Completed NCT01027481 Phase 4 Lucentis
41 Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation Completed NCT02962999 Phase 4 Ketamine;Saline
42 Influence of Cardiopulmonary Bypass, and Sevoflurane or Propofol Anesthesia, on Tissue Oxygen Saturation. Completed NCT02593448 Phase 4
43 To Evaluate the Effect of Chlorhexidine-benzidamine Administration Completed NCT03253497 Phase 4 Chlorobenzene Liquid
44 The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia Completed NCT01091571 Phase 4 Dipyridamole;Placebo
45 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4 early enteral nutrition;Delayed enteral nutrition
46 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4 Erythropoietin
47 Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients Completed NCT01996124 Phase 4 Indacaterol Fumarate;Placebo
48 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
49 Effect-site Concentration of Remifentanil for Smooth Induction With Desflurane Completed NCT02379715 Phase 4 Remifentanil;Desflurane
50 Bispectral Index and Clinical Parameters Evaluation in Dental Procedures Completed NCT02671578 Phase 4 Nitrous Oxide

Search NIH Clinical Center for Hypoxia

Genetic Tests for Hypoxia

Anatomical Context for Hypoxia

MalaCards organs/tissues related to Hypoxia:

41
Endothelial, Lung, Brain, Prostate, Heart, Kidney, Liver

Publications for Hypoxia

Articles related to Hypoxia:

(show top 50) (show all 7248)
# Title Authors Year
1
Hypoxia-inducible factor-1 (HIF-1) activation in myeloid cells accelerates DSS-induced colitis progression in mice. ( 29967068 )
2018
2
Retinoic acid receptor-related orphan receptor RORI+ regulates differentiation and survival of keratinocytes during hypoxia. ( 28332183 )
2018
3
Nocturnal cerebral hypoxia in obstructive sleep apnoea: a randomised controlled trial. ( 29700104 )
2018
4
The role of the ATPase inhibitor factor 1 (IF<sub>1</sub>) in cancer cells adaptation to hypoxia and anoxia. ( 29097244 )
2018
5
ERK1/2 and Akt phosphorylation were essential for MGF E peptide regulating cell morphology and mobility but not proangiogenic capacity of BMSCs under severe hypoxia. ( 29441602 )
2018
6
Role of hypoxia-inducible factor-1 in the development of renal fibrosis in mouse obstructed kidney: Special references to HIF-1 dependent gene expression of profibrogenic molecules. ( 29352658 )
2018
7
Tibial dyschondroplasia is closely related to suppression of expression of hypoxia-inducible factors 1I+, 2I+, and 3I+ in chickens. ( 28693310 )
2018
8
Hypoxia-Induced Signaling Activation in Neurodegenerative Diseases: Targets for New Therapeutic Strategies. ( 29439330 )
2018
9
Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. ( 29433520 )
2018
10
Twist1 in Hypoxia-induced Pulmonary Hypertension through Transforming Growth Factor-I^-Smad Signaling. ( 28915063 )
2018
11
Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia. ( 29251717 )
2018
12
FAT10 attenuates hypoxia-induced cardiomyocyte apoptosis by stabilizing caveolin-3. ( 29438664 )
2018
13
Hypoxia and myelination deficits in the developing brain. ( 29964158 )
2018
14
LncRNA TUG1 serves an important role in hypoxia-induced myocardial cell injury by regulating the miRa89145a895pa89Binp3 axis. ( 29207102 )
2018
15
Hypoxia induces production of citrullinated proteins in human fibroblast-like synoviocytes through regulating HIF1I+. ( 29484680 )
2018
16
Combined fetal inflammation and postnatal hypoxia causes myelin deficits and autism-like behavior in a rat model of diffuse white matter injury. ( 28925578 )
2018
17
Tissue-penetrating, hypoxia-responsive echogenic polymersomes for drug delivery to solid tumors. ( 29968262 )
2018
18
Yap-Hippo pathway regulates cerebral hypoxia-reoxygenation injury in neuroblastoma N2a cells via inhibiting ROCK1/F-actin/mitochondrial fission pathways. ( 29796942 )
2018
19
Multiple myeloma cells adapted to long-exposure of hypoxia exhibit stem cell characters with TGF-I^/Smad pathway activation. ( 29309790 )
2018
20
Hypoxia-inducible transcription factors in fish: expression, function and interconnection with the circadian clock. ( 29973414 )
2018
21
Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1I+ in non-small cell lung cancer A549 cells. ( 29971135 )
2018
22
Hypoxia promotes breast cancer cell invasion through HIF-1I+-mediated up-regulation of the invadopodial actin bundling protein CSRP2. ( 29976963 )
2018
23
Deregulation of Hexokinase II Is Associated with Glycolysis, Autophagy, and the Epithelial-Mesenchymal Transition in Tongue Squamous Cell Carcinoma under Hypoxia. ( 29682563 )
2018
24
Chronic intermittent hypoxia promotes myocardial ischemia-related ventricular arrhythmias and sudden cardiac death. ( 29445096 )
2018
25
Retroperitoneal paraganglioma in a patient with Fontan: The hypoxia connection. ( 29922019 )
2018
26
Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SHSY-5Y by inhibiting PI3K/Akt-dependent glycolysis. ( 29426376 )
2018
27
TGF-b1 or Hypoxia Enhance Glucose Metabolism and Lactate Production via HIF1A Signaling in Tendon Cells. ( 29447016 )
2018
28
The effects of sleeping position, maternal smoking and substance misuse on the ventilatory response to hypoxia in the newborn period. ( 29976971 )
2018
29
Overexpression of FGF19 alleviates hypoxia/reoxygenation-induced injury of cardiomyocytes by regulating GSK-3I^/Nrf2/ARE signaling. ( 29964017 )
2018
30
Hypoxia-Inducible Factor-1I+ (HIF-1I+) Expression on Endothelial Cells in Juvenile Nasopharyngeal Angiofibroma: A Review of 70 cases and Tissue Microarray Analysis. ( 29717655 )
2018
31
Hypoxia-increased RAGE expression regulates chemotaxis and pro-inflammatory cytokines release through nuclear translocation of NF-I_ B and HIF1I+ in THP-1a8^cells. ( 29258824 )
2018
32
Dobutamine treatment reduces inflammation in the preterm fetal sheep brain exposed to acute hypoxia. ( 29976968 )
2018
33
Association of EGLN1 genetic polymorphisms with SpO<sub>2</sub> responses to acute hypobaric hypoxia in a Japanese cohort. ( 29625625 )
2018
34
Atrial Arrhythmias and Autonomic Dysfunction in Rats Exposed to Chronic Intermittent Hypoxia. ( 29424572 )
2018
35
Brain changes due to hypoxia during light anaesthesia can be prevented by deepening anaesthesia; a study in rats. ( 29451906 )
2018
36
Neuronal nitric oxide synthase inhibition reduces brain damage by promoting collateral recruitment in a cerebral hypoxia-ischemia mice model. ( 29863262 )
2018
37
Dendrobium nobile Lindley and its bibenzyl component moscatilin are able to protect retinal cells from ischemia/hypoxia by dowregulating placental growth factor and upregulating Norrie disease protein. ( 29933759 )
2018
38
Mesenchymal stem cells protect against hypoxia-ischemia brain damage by enhancing autophagy through BDNF/mTOR signaling pathway. ( 29451335 )
2018
39
Cerebral blood flow, oxygen metabolism and lactate during hypoxia in patients with obstructive sleep apnea. ( 29309697 )
2018
40
Metabolic implications of hypoxia and pseudohypoxia in pheochromocytoma and paraganglioma. ( 29450727 )
2018
41
Ameliorative Effect of Trans-Sinapic Acid and its Protective Role in Cerebral Hypoxia in Aluminium Chloride Induced Dementia of Alzheimer's Type. ( 29521253 )
2018
42
Hypoxia-Induced TPM2 Methylation is Associated with Chemoresistance and Poor Prognosis in Breast Cancer. ( 29414807 )
2018
43
Chronic intermittent hypoxia and renovascular hypertension: A case of one plus one equals one-half! ( 29377392 )
2018
44
Radioprotective Effects of Dermatan Sulfate in a Preclinical Model of Oral Mucositis-Targeting Inflammation, Hypoxia and Junction Proteins without Stimulating Proliferation. ( 29882770 )
2018
45
Hypoxia-inducible KDM3A addiction in multiple myeloma. ( 29444873 )
2018
46
Hypoxia-induced activation of Twist/miR-214/E-cadherin axis promotes renal tubular epithelial cell mesenchymal transition and renal fibrosis. ( 29277613 )
2018
47
The relationship between plasma vascular endothelial growth factor and erythrocyte 2,3-bisphosphoglycerate: The putative role of chronic hypoxia. ( 29447940 )
2018
48
Muscle hypertrophy following blood flow-restricted low force isometric electrical stimulation in rat tibialis anterior: Role for muscle hypoxia. ( 29565774 )
2018
49
Hypoxia Promotes Ectopic Adhesion Ability of Endometrial Stromal Cells via TGF-I^1/Smad Signalling in Endometriosis. ( 29438550 )
2018
50
Pathogenesis of Abnormal Hepatic Lipid Metabolism Induced by Chronic Intermittent Hypoxia in Rats and the Therapeutic Effect of N-Acetylcysteine. ( 29968701 )
2018

Variations for Hypoxia

Expression for Hypoxia

Search GEO for disease gene expression data for Hypoxia.

Pathways for Hypoxia

Pathways related to Hypoxia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.95 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
2 12.83 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
3
Show member pathways
12.47 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
4 12.24 ARNT EGLN1 EPAS1 HIF1A HIF1AN MTOR
6 11.92 ARNT EGLN1 EGLN2 EGLN3 EP300 HIF1A
7 11.84 ARNT EGLN1 EP300 HIF1A HIF1AN
8 11.83 EP300 HIF1A MTOR
9
Show member pathways
11.79 ARNT EPAS1 HIF1A VHL
10 11.72 ARNT CITED2 EGLN1 EGLN3 EP300 HIF1A
11
Show member pathways
11.59 ARNT EP300 HIF1A
12 11.54 HIF1A MTOR TIGAR
13 11.39 ARNT EP300 HIF1A
14 11.38 ARNT EGLN1 HIF1A HIF1AN
15
Show member pathways
11.36 ARNT CITED2 EGLN3 EP300 EPAS1 HIF1A
16 11.29 ARNT EGLN1 EGLN2 EP300 HIF1A HIF1AN
17 10.98 ARNT HIF1A HIF1AN HIF3A VHL
18 10.81 EPAS1 VHL
19 10.81 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
20 10.53 HIF1A HIF1AN

GO Terms for Hypoxia

Cellular components related to Hypoxia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.97 EGLN1 EGLN3 EP300 EPAS1 HIF1A HIF1AN
2 nucleus GO:0005634 9.86 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
3 transcription factor complex GO:0005667 9.56 ARNT EP300 EPAS1 HIF1A
4 nucleoplasm GO:0005654 9.53 ARNT CITED2 EGLN2 EGLN3 EP300 EPAS1
5 RNA polymerase II transcription factor complex GO:0090575 9.5 ARNT HIF1A RORA

Biological processes related to Hypoxia according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.93 EPAS1 HIF1A HIF3A PSMA7 VHL
2 angiogenesis GO:0001525 9.88 EPAS1 HIF1A HIF3A RORA
3 rhythmic process GO:0048511 9.8 EP300 KMT2A RORA
4 positive regulation of endothelial cell proliferation GO:0001938 9.75 ARNT HIF1A MTOR
5 cellular response to hypoxia GO:0071456 9.7 EPAS1 HIF1A HILPDA HYOU1 MTOR RORA
6 visual learning GO:0008542 9.69 HIF1A KMT2A MTOR
7 positive regulation of vascular endothelial growth factor production GO:0010575 9.65 ARNT HIF1A RORA
8 negative regulation of reactive oxygen species metabolic process GO:2000378 9.63 HIF1A TIGAR
9 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.62 ARNT HIF1A
10 positive regulation of glycolytic process GO:0045821 9.62 ARNT HIF1A
11 mRNA transcription by RNA polymerase II GO:0042789 9.61 ARNT HIF1A
12 embryonic hemopoiesis GO:0035162 9.61 HIF1A KMT2A
13 response to hypoxia GO:0001666 9.61 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
14 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.58 ARNT EPAS1 HIF1A
15 oxygen homeostasis GO:0032364 9.56 EGLN1 HIF1A
16 embryonic placenta development GO:0001892 9.56 ARNT CITED2 EPAS1 HIF1A
17 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.54 EGLN1 EGLN2 EGLN3
18 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.5 CITED2 HIF1AN VHL
19 positive regulation of hormone biosynthetic process GO:0046886 9.49 ARNT HIF1A
20 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.4 ARNT EGLN1 EGLN2 EGLN3 EP300 EPAS1
21 regulation of transcription, DNA-templated GO:0006355 10.25 ARNT CITED2 EP300 EPAS1 HIF1A HIF1AN
22 transcription, DNA-templated GO:0006351 10.24 ARNT CITED2 EP300 EPAS1 HIF1A HIF1AN
23 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 ARNT CITED2 EGLN1 EP300 EPAS1 HIF1A
24 oxidation-reduction process GO:0055114 10.04 EGLN1 EGLN2 EGLN3 HIF1AN HIGD1A P4HTM
25 negative regulation of apoptotic process GO:0043066 10 CITED2 HIF1A HIGD1A HYOU1 VHL
26 transcription by RNA polymerase II GO:0006366 10 CITED2 EP300 EPAS1 HIF1A HIF3A KMT2A
27 positive regulation of transcription, DNA-templated GO:0045893 10 ARNT CITED2 EP300 HIF1A KMT2A RORA

Molecular functions related to Hypoxia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.92 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
2 transcription factor binding GO:0008134 9.85 ARNT EP300 EPAS1 HIF1A RORA VHL
3 protein dimerization activity GO:0046983 9.8 ARNT EPAS1 HIF1A HIF3A
4 iron ion binding GO:0005506 9.72 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 EGLN1 EGLN2 EGLN3 P4HTM
6 histone acetyltransferase binding GO:0035035 9.61 CITED2 EPAS1 HIF1A
7 dioxygenase activity GO:0051213 9.55 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
8 oxygen sensor activity GO:0019826 9.46 EGLN2 HIF1AN
9 peptidyl-proline 4-dioxygenase activity GO:0031545 9.43 EGLN1 EGLN2 EGLN3
10 L-ascorbic acid binding GO:0031418 9.26 EGLN1 EGLN2 EGLN3 P4HTM
11 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.02 EGLN1 EGLN2 EGLN3 HIF1AN P4HTM
12 protein binding GO:0005515 10.44 ARNT CITED2 EGLN1 EGLN2 EGLN3 EP300
13 DNA binding transcription factor activity GO:0003700 10.02 ARNT CITED2 EPAS1 HIF1A HIF3A KMT2A

Sources for Hypoxia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29